Background: α1-Adrenoceptor blockers (α1Bs) are used for the treatment of benign prostatic hyperplasia and hypertension, but they are known to cause hypotension-related adverse events. The objective of the present s...Background: α1-Adrenoceptor blockers (α1Bs) are used for the treatment of benign prostatic hyperplasia and hypertension, but they are known to cause hypotension-related adverse events. The objective of the present study was to evaluate the onset time profiles for syncope associated with the use of α1Bs. Methods: We analyzed the data obtained from?the Japanese Adverse Drug Event Report (JADER) database for a period from April 2004 until November 2016 and calculated reporting odds ratios (RORs) for eight α1Bs available on the Japanese market, using disproportionality analysis. Moreover, time information recorded in the JADER database was analyzed to evaluate the onset times of adverse events. Results: In total, 186,724 reports for males older than 20 years were analyzed. Significant RORs for syncope, with 95% confidence intervals, were obtained for naftopidil (2.53, 1.81 - 3.53), silodosin (4.24, 2.37 - 5.20), and tamsulosin (2.22, 1.75 - 2.81). The median onset times of syncope for naftopidil, silodosin, and tamsulosin were 37, 26, and 108 days, respectively. The shape parameters obtained by fitting the data for the three α1Bs to the Weibull distribution were all less than 1.0, indicating that all these drugs could be classified as the early failure type. The cumulative incidence rates showed that the onset times of syncope tended to be similar among the three α1Bs. Conclusions: Patients treated with selective α1Bs should be closely monitored for 100 days, especially in the first 20 to 40 days after initiation of silodosin or naftopidil. This information may be useful for patients and healthcare professionals in preventing syncope due to the use of selective α1Bs.展开更多
Objective:Ovarian cancer is one of the leading causes of death in women,because of late diagnosis,recurrence and resistance to chemotherapy.Therefore,it's necessary to design a novel sensitive and specific maker t...Objective:Ovarian cancer is one of the leading causes of death in women,because of late diagnosis,recurrence and resistance to chemotherapy.Therefore,it's necessary to design a novel sensitive and specific maker to diagnose and treat patients of ovarian cancer.However,this study intends to explore the expression and prognostic value of ENO1 in ovarian cancer.Method:ENO1 data were collected from Oncomine database,and then were performed subgroup analysis and systematic analysis.Meanwhile,the prognostic significance of ENO1 was analyzed by an online survival analysis tool"Kaplan-Meier Plotter"(KM plotter)database.Results:In Oncomine database,a total of 14 studies were involved ENO1 in ovarian cancer tissues and normal tissues,including a total of 1001 samples.Comparing with normal tissues,ENO1 expression is higher(P<0.05).Moreover,the overall survival of ENO1 high expression in ovarian cancer is closely related with high survival(P<0.05).Further study indicated that ENO1 expression showed negative relation to the prognosis of serous ovarian cancer patients while ENO1 expression showed no effects on the prognosis of endometrioid ovarian cancer patients.Conclusion:Through exploration of tumor gene information in Oncomine database,ENO1 was found highly expressed in ovarian cancer and related to the prognosis of ovarian cancer,which might be a new marker for ovarian cancer prognosis and alternative drug therapy.展开更多
文摘Background: α1-Adrenoceptor blockers (α1Bs) are used for the treatment of benign prostatic hyperplasia and hypertension, but they are known to cause hypotension-related adverse events. The objective of the present study was to evaluate the onset time profiles for syncope associated with the use of α1Bs. Methods: We analyzed the data obtained from?the Japanese Adverse Drug Event Report (JADER) database for a period from April 2004 until November 2016 and calculated reporting odds ratios (RORs) for eight α1Bs available on the Japanese market, using disproportionality analysis. Moreover, time information recorded in the JADER database was analyzed to evaluate the onset times of adverse events. Results: In total, 186,724 reports for males older than 20 years were analyzed. Significant RORs for syncope, with 95% confidence intervals, were obtained for naftopidil (2.53, 1.81 - 3.53), silodosin (4.24, 2.37 - 5.20), and tamsulosin (2.22, 1.75 - 2.81). The median onset times of syncope for naftopidil, silodosin, and tamsulosin were 37, 26, and 108 days, respectively. The shape parameters obtained by fitting the data for the three α1Bs to the Weibull distribution were all less than 1.0, indicating that all these drugs could be classified as the early failure type. The cumulative incidence rates showed that the onset times of syncope tended to be similar among the three α1Bs. Conclusions: Patients treated with selective α1Bs should be closely monitored for 100 days, especially in the first 20 to 40 days after initiation of silodosin or naftopidil. This information may be useful for patients and healthcare professionals in preventing syncope due to the use of selective α1Bs.
文摘Objective:Ovarian cancer is one of the leading causes of death in women,because of late diagnosis,recurrence and resistance to chemotherapy.Therefore,it's necessary to design a novel sensitive and specific maker to diagnose and treat patients of ovarian cancer.However,this study intends to explore the expression and prognostic value of ENO1 in ovarian cancer.Method:ENO1 data were collected from Oncomine database,and then were performed subgroup analysis and systematic analysis.Meanwhile,the prognostic significance of ENO1 was analyzed by an online survival analysis tool"Kaplan-Meier Plotter"(KM plotter)database.Results:In Oncomine database,a total of 14 studies were involved ENO1 in ovarian cancer tissues and normal tissues,including a total of 1001 samples.Comparing with normal tissues,ENO1 expression is higher(P<0.05).Moreover,the overall survival of ENO1 high expression in ovarian cancer is closely related with high survival(P<0.05).Further study indicated that ENO1 expression showed negative relation to the prognosis of serous ovarian cancer patients while ENO1 expression showed no effects on the prognosis of endometrioid ovarian cancer patients.Conclusion:Through exploration of tumor gene information in Oncomine database,ENO1 was found highly expressed in ovarian cancer and related to the prognosis of ovarian cancer,which might be a new marker for ovarian cancer prognosis and alternative drug therapy.
